Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90.4M
-
Number of holders
-
26
-
Total 13F shares, excl. options
-
9.83M
-
Shares change
-
+9.83M
-
Total reported value, excl. options
-
$198M
-
Value change
-
+$198M
-
Number of buys
-
24
-
Price
-
$20.26
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2016
26 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2016.
CRISPR Therapeutics AG - Common Stock (CRSP) has 26 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.83M shares
of 90.4M outstanding shares and own 10.87% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.22M shares), Abingworth LLP (2.6M shares), Clough Capital Partners L P (839K shares), WELLINGTON MANAGEMENT GROUP LLP (744K shares), FRANKLIN RESOURCES INC (729K shares), New Leaf Venture Partners, L.L.C. (586K shares), ORBIMED ADVISORS LLC (372K shares), Novo A/S (223K shares), LORD, ABBETT & CO. LLC (212K shares), and Vivo Capital, LLC (149K shares).
This table shows the top 26 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.